RAF Gene Mutation clinical trials at UCSF
1 research study open to eligible people
Raf gene mutations change how cells grow. UCSF is testing a new drug, NST-628, in people with tumors to learn about its safety and effects. The study involves taking NST-628 tablets and having doctors monitor tumor response and side effects.
NST-628 Oral Tablets in Subjects With Solid Tumors
open to eligible people ages 18 years and up
This is a two-part Phase 1, open label, multi-center, single arm, non-randomized, multiple dose, safety, pharmacokinetic (PK) and preliminary efficacy study of single agent NST-628 in adult patients with MAPK pathway mutated/dependent advanced solid tumors who have exhausted standard treatment options.
San Francisco 5391959, California 5332921 and other locations
Our lead scientists for RAF Gene Mutation research studies include Varun Monga.
Last updated: